Medical network February 28th hearing in recent years, with the trend of aging population increased, the potential demand for coronary heart disease drug market has also increased, the market size is rising year by year. According to CMH research data show that in 2015, China's coronary heart disease market size of $63 billion 200 million. Step pharmaceutical market share ranking in the first drug injection, oral route of administration in the performance is more excellent.
Market size is rising year by year
Coronary heart disease is more prevalent in the elderly population in China, in recent years, the trend of aging population, and further improve the market demand for coronary heart disease. In view of the use of drugs in the elderly, especially in patients with consumption habits and recognition of Chinese medicine in the treatment of coronary heart disease has its own advantages, its market size is rising year by year. According to CMH research data show that in 2015, China's coronary heart disease market size of $63 billion 200 million.
Figure 1 2013-2016E coronary heart disease market size (unit: 100 million yuan)
The route of administration accounted for more than half
From the route of administration, the current injection coronary heart disease medicine market is higher than the proportion of oral medication, but due to the auxiliary drug list was included in the most around, the use is restricted, so the injection Market proportion show a declining trend in future.
Figure 2 the proportion of coronary heart disease proprietary Chinese medicine administration
Top10 companies and brands of injectable drugs
According to CMH research data show that 2015 of the total market size of coronary heart disease in China before the injection of drugs in the first half of the total size of ten companies was $25 billion 400 million, an increase of 5.2%, accounting for the overall market share of more than a high degree of concentration. Step group accounted for 16.5% of the market leader Huarun, followed by Top10 pharmaceutical enterprises; pharmaceutical and Harbin Pharmaceutical Group in Jiangsu, grew most rapidly.
Table 12015 coronary heart disease proprietary Chinese medicine market injection Top10 enterprise
Note: EI to 100 as the benchmark, indicating the average level of development of the category; EI>100 that the product development is higher than the average level; EI<100 indicates that the product development is below average
Dan Hong injection (step) is the leading brand of coronary heart disease in the Chinese market injection of drugs, 2015 to 16.5% of the market share has further opened up with the distance from other brands. Shenmai injection (Shanghai Pharmaceutical Group) and Shengmai Injection (Jiangsu pharmaceutical Jiangsu) and Danshen injection (Harbin) market rapid growth.
Table 22015 coronary heart disease proprietary Chinese medicine injection Top10 brand market
Oral administration of Top10 enterprises and brands
According to the health CMH monitoring data show that 2015 of the total market size of coronary heart disease market before the oral administration of drugs for the first ten companies was $16 billion 540 million, an increase of 13.2%, faster than the growth rate of injectable drugs. Tasly and Yiling pharmaceutical in the first echelon two racing together bridle to bridle, the market competition is more intense, but the rose less than Yiling pharmaceutical, Yiling pharmaceutical is expected in the future will go beyond the occupation of taking medicine Tasly, Chinese medicine market dominance in coronary heart disease.
Table 32015 coronary heart disease market Chinese medicine oral administration Top10 enterprise
From the oral administration of TOP10 brand, compound Danshen Dripping Pills (the) share of 0.4 percentage points year-on-year loss in 2015, but the position advantage is still evident; the rest of the brand position difference competition, Ginkgo Biloba Leaves Extract Tablets (Yangtze) and Salvia Baoxin tea (Black Dragon God Jiangbei odd pharmaceutical) gratifying growth.
Table 42015 coronary heart disease market Chinese medicine oral administration Top10 brand |
